25 Feb 2021
Norway, one of the co-founders of CEPI, announced this week that it will contribute US $24 million (NOK 200 million) towards CEPI’s R&D efforts to future-proof vaccines against current and future variants of the SARS-CoV-2 virus.
The financial commitment follows the US $145 million (EUR 120 million) donation announced by the Government of Germany last week following the extraordinary G7 virtual summit to support CEPI’s COVID-19 vaccine programmes. The funding is as part of a wider US $1.82 billion (EUR 1.5 billion) donation package to partners of the Access to COVID-19 Tools (ACT) Accelerator.
These investments come at a critical time of the COVID-19 pandemic, with CEPI seeking to expand its efforts and respond to the rapidly evolving crisis.
Chief Executive Officer, CEPI
Both Norway and Germany are long-term partners and two of the biggest investors in CEPI’s work. Norway was one of CEPI’s founding members when the organisation launched, in the wake of the 2014-16 Ebola epidemic, as the result of a consensus that a coordinated, international, and intergovernmental plan was needed to develop and deploy new vaccines to prevent future epidemics. The Government of Germany also provided significant financial contributions to advance CEPI’s mission in 2017 through the German Federal Minister of Education and Research (Bundesministerium für Bildung und Forschung; BMBF) and again in 2020 to support the establishment of CEPI’s COVID-19 vaccine portfolio.
The new funding will support CEPI’s goal of raising $1 billion in 2021 to carry out critical R&D to future-proof vaccines against emerging variants, maximise the available supply of vaccines, and fill in current clinical research and development gaps to optimise the use of the vaccines we have.